Fig. 2From: Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac studyOccurrence of symptoms during the study period. Percentage of patients with mild, moderate and severe dyspnea (a) and cough (b) at baseline and 6, 9 and 12 months. Percentages were based on patients remaining in the study at the respective timepointsBack to article page